Top

Neurological Sciences

Published in:

01-09-2019 | Parkinson's Disease | Original Article

Association of homocysteine, folate, and white matter hyperintensities in Parkinson’s patients with different motor phenotypes

Authors: Yuan Shen, Zhi-feng Dong, Ping-Lei Pan, Gang Xu, Jun-Ying Huang, Chun-Feng Liu

Published in: Neurological Sciences | Issue 9/2019

Abstract

Objective

To investigate the association of homocysteine (Hcy), folate, and white matter hyperintensities in Parkinson’s disease (PD) with different motor phenotypes.

Methods

Of the PD patients, 176 were included. Based on the Unified Parkinson’s Disease Rating Scale, the PD patients were classified into postural instability gait disorder (PIGD) and non-PIGD phenotypes. According to the Fazekas score, patients were divided into the none/mild white matter hyperintensity (WMH) group and the moderate/severe WMH group. The relationship of Hcy, folate, and white matter hyperintensities (WMHs), and the motor phenotype of PD were analyzed.

Results

PD-PIGD patients had higher proportion of moderate/severe WMHs, Hcy levels, and lower folate levels than PD-non-PIGD patients (p all ≤ 0.001). In the subgroup analysis, patients with both PD-PIGD and moderate/severe WMHs had the highest Hcy and lowest folate levels compared with others. Binary logistic regression analysis showed that age, folate, and Hcy were independent risk factors for WMHs. In an a priori-determined stratified analysis, after adjustment for confounding factors, the odds ratio of WMHs was 8.01 (95% CI 2.700–23.767, p trend = 0.001) in the patients with Hcy levels in the highest quintile compared with the lowest quintile and 16.81 (95% CI 4.74–59.65, p trend < 0.001) in the patients with folate levels in the lowest quintile compared with the highest quintile.

Conclusions

Our data showed a close association between WMHs and Hcy, folate especially in PD-PIGD patients. It can be speculated that higher Hcy and lower folate probably played important roles in the development of WMHs and motor heterogeneity in PD.

Kotagal V, Albin RL, Muller ML, Koeppe RA, Frey KA, Bohnen NI (2014) Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease. Neurology 82(17):1514–1520. https://doi.org/10.1212/wnl.0000000000000356 CrossRefPubMedPubMedCentral

Vesely B, Antonini A, Rektor I (2016) The contribution of white matter lesions to Parkinson’s disease motor and gait symptoms: a critical review of the literature. J Neural Transm(Vienna, Austria : 1996) 123(3):241–250. https://doi.org/10.1007/s00702-015-1470-9 CrossRef

Vesely B, Rektor I (2016) The contribution of white matter lesions (WML) to Parkinson’s disease cognitive impairment symptoms: a critical review of the literature. Parkinsonism Relat Disord 22(Suppl 1):S166–S170. https://doi.org/10.1016/j.parkreldis.2015.09.019 CrossRefPubMed

Grammas P, Martinez J, Miller B (2011) Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev Mol Med 13:e19. https://doi.org/10.1017/s1462399411001918 CrossRefPubMed

Nelson AR, Sweeney MD, Sagare AP, Zlokovic BV (2016) Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer’s disease. Biochim Biophys Acta 1862(5):887–900. https://doi.org/10.1016/j.bbadis.2015.12.016 CrossRefPubMed

Sagare AP, Bell RD, Zlokovic BV (2012) Neurovascular dysfunction and faulty amyloid beta-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med 2(10). https://doi.org/10.1101/cshperspect.a011452

Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV (2015) Establishment and dysfunction of the blood-brain barrier. Cell 163(5):1064–1078. https://doi.org/10.1016/j.cell.2015.10.067 CrossRefPubMedPubMedCentral

Zlokovic BV (2008) The blood-brain barrier in health an Neuron d chronic neurodegenerative disorders. Neuron 57(2):178–201. https://doi.org/10.1016/j.neuron.2008.01.003 CrossRefPubMed

DeCarli C, Miller BL, Swan GE, Reed T, Wolf PA, Garner J, Jack L, Carmelli D (1999) Predictors of brain morphology for the men of the NHLBI twin study. Stroke 30(3):529–536CrossRefPubMed

10.

Dufouil C, Chalmers J, Coskun O, Besancon V, Bousser MG, Guillon P, MacMahon S, Mazoyer B, Neal B, Woodward M, Tzourio-Mazoyer N, Tzourio C (2005) Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) magnetic resonance imaging substudy. Circulation 112(11):1644–1650. https://doi.org/10.1161/circulationaha.104.501163 CrossRefPubMed

11.

van Harten B, Oosterman JM, Potter van Loon BJ, Scheltens P, Weinstein HC (2007) Brain lesions on MRI in elderly patients with type 2 diabetes mellitus. Eur Neurol 57(2):70–74. https://doi.org/10.1159/000098054 CrossRefPubMed

12.

Gustafson DR, Steen B, Skoog I (2004) Body mass index and white matter lesions in elderly women. An 18-year longitudinal study. Int Psychogeriatr 16(3):327–336CrossRefPubMed

13.

Jagust W, Harvey D, Mungas D, Haan M (2005) Central obesity and the aging brain. Arch Neurol 62(10):1545–1548. https://doi.org/10.1001/archneur.62.10.1545 CrossRefPubMed

14.

Knopman DS, Mosley TH, Catellier DJ, Sharrett AR (2005) Cardiovascular risk factors and cerebral atrophy in a middle-aged cohort. Neurology 65(6):876–881. https://doi.org/10.1212/01.wnl.0000176074.09733.a8 CrossRefPubMed

15.

Cervellati C, Romani A, Seripa D, Cremonini E, Bosi C, Magon S, Passaro A, Bergamini CM, Pilotto A, Zuliani G (2014) Oxidative balance, homocysteine, and uric acid levels in older patients with late onset Alzheimer’s disease or vascular dementia. J Neurol Sci 337(1–2):156–161. https://doi.org/10.1016/j.jns.2013.11.041 CrossRefPubMed

16.

Song IU, Kim JS, Park IS, Kim YD, Cho HJ, Chung SW, Lee KS (2013) Clinical significance of homocysteine (Hcy) on dementia in Parkinson’s disease (PD). Arch Gerontol Geriatr 57(3):288–291. https://doi.org/10.1016/j.archger.2013.04.015 CrossRefPubMed

17.

Kirbas S, Kirbas A, Tufekci A, Cumhur Cure M, Cakmak S, Yazici T, Cure E (2016) Serum levels of homocysteine, asymmetric dimethylarginine and nitric oxide in patients with Parkinson’s disease. Acta Clin Belg 71(2):71–75. https://doi.org/10.1080/17843286.2016.1138592 CrossRefPubMed

18.

Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J, Lamet I, Pagonabarraga J, Toledo JB, Garcia-Garcia D, Clavero P, Samaranch L, Irurzun C, Matsubara JM, Irigoien J, Bescos E, Kulisevsky J, Perez-Tur J, Obeso JA (2009) Homocysteine and cognitive impairment in Parkinson’s disease: a biochemical, neuroimaging, and genetic study. Mov Disord : Off J Mov Disord Soc 24(10):1437–1444. https://doi.org/10.1002/mds.22522 CrossRef

19.

Bhatia P, Singh N (2015) Homocysteine excess: delineating the possible mechanism of neurotoxicity and depression. Fundam Clin Pharmacol 29(6):522–528. https://doi.org/10.1111/fcp.12145 CrossRefPubMed

20.

Curro M, Gugliandolo A, Gangemi C, Risitano R, Ientile R, Caccamo D (2014) Toxic effects of mildly elevated homocysteine concentrations in neuronal-like cells. Neurochem Res 39(8):1485–1495. https://doi.org/10.1007/s11064-014-1338-7 CrossRefPubMed

21.

Scott TM, Tucker KL, Bhadelia A, Benjamin B, Patz S, Bhadelia R, Liebson E, Price LL, Griffith J, Rosenberg I, Folstein MF (2004) Homocysteine and B vitamins relate to brain volume and white-matter changes in geriatric patients with psychiatric disorders. Am J Geriatr Psychiatry : Off J Am Assoc Geriatr Psychiatry 12(6):631–638. https://doi.org/10.1176/appi.ajgp.12.6.631 CrossRef

22.

Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, Breteler MM (2002) Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam Scan Study. Ann Neurol 51(3):285–289CrossRefPubMed

23.

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184CrossRefPubMedPubMedCentral

24.

Zijlmans JC, Daniel SE, Hughes AJ, Revesz T, Lees AJ (2004) Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord : Off J Mov Disord Soc 19(6):630–640. https://doi.org/10.1002/mds.20083 CrossRef

25.

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord : Off J Mov Disord Soc 25(15):2649–2653. https://doi.org/10.1002/mds.23429 CrossRef

26.

Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I, Stern M, Tanner C, Weiner W, Parkinson Study Group (1990) Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40(10):1529–1534CrossRefPubMed

27.

Feng L, Isaac V, Sim S, Ng TP, Krishnan KR, Chee MW (2013) Associations between elevated homocysteine, cognitive impairment, and reduced white matter volume in healthy old adults. Am J Geriatr Psychiatry : Off J Am Assoc Geriatr Psychiatry 21(2):164–172. https://doi.org/10.1016/j.jagp.2012.10.017 CrossRef

28.

Kloppenborg RP, Geerlings MI, Visseren FL, Mali WP, Vermeulen M, van der Graaf Y, Nederkoorn PJ (2014) Homocysteine and progression of generalized small-vessel disease: the SMART-MR study. Neurology 82(9):777–783. https://doi.org/10.1212/wnl.0000000000000168 CrossRefPubMed

29.

Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease. J Neurochem 80(1):101–110CrossRefPubMed

30.

Haghdoost-Yazdi H, Fraidouni N, Faraji A, Jahanihashemi H, Sarookhani M (2012) High intake of folic acid or complex of B vitamins provides anti-parkinsonism effect: no role for serum level of homocysteine. Behav Brain Res 233(2):375–381. https://doi.org/10.1016/j.bbr.2012.05.011 CrossRefPubMed

31.

Zhang CE, Wei W, Liu YH, Peng JH, Tian Q, Liu GP, Zhang Y, Wang JZ (2009) Hyperhomocysteinemia increases beta-amyloid by enhancing expression of gamma-secretase and phosphorylation of amyloid precursor protein in rat brain. Am J Pathol 174(4):1481–1491. https://doi.org/10.2353/ajpath.2009.081036 CrossRefPubMedPubMedCentral

32.

Zhuo JM, Portugal GS, Kruger WD, Wang H, Gould TJ, Pratico D (2010) Diet-induced hyperhomocysteinemia increases amyloid-beta formation and deposition in a mouse model of Alzheimer’s disease. Curr Alzheimer Res 7(2):140–149CrossRefPubMedPubMedCentral

33.

Lee SJ, Kim JS, Lee KS, An JY, Kim W, Kim YI, Kim BS, Jung SL (2009) The severity of leukoaraiosis correlates with the clinical phenotype of Parkinson’s disease. Arch Gerontol Geriatr 49(2):255–259. https://doi.org/10.1016/j.archger.2008.09.005 CrossRefPubMed

34.

Bohnen NI, Muller ML, Zarzhevsky N, Koeppe RA, Bogan CW, Kilbourn MR, Frey KA, Albin RL (2011) Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson’s disease. Brain : J Neurol 134(Pt 8):2358–2365. https://doi.org/10.1093/brain/awr139 CrossRef

35.

Herman T, Rosenberg-Katz K, Jacob Y, Auriel E, Gurevich T, Giladi N, Hausdorff JM (2013) White matter hyperintensities in Parkinson’s disease: do they explain the disparity between the postural instability gait difficulty and tremor dominant subtypes? PLoS One 8(1):e55193. https://doi.org/10.1371/journal.pone.0055193 CrossRefPubMedPubMedCentral

36.

Song IU, Kim YD, Cho HJ, Chung SW (2013) The effects of silent cerebral ischemic lesions on the prognosis of idiopathic Parkinson’s disease. Parkinsonism Relat Disord 19(8):761–763. https://doi.org/10.1016/j.parkreldis.2013.04.006 CrossRefPubMed

37.

Shine JM, Matar E, Ward PB, Frank MJ, Moustafa AA, Pearson M, Naismith SL, Lewis SJ (2013) Freezing of gait in Parkinson’s disease is associated with functional decoupling between the cognitive control network and the basal ganglia. Brain J Neurol 136(Pt 12):3671–3681. https://doi.org/10.1093/brain/awt272 CrossRef

38.

Whitwell JL, Master AV, Avula R, Kantarci K, Eggers SD, Edmonson HA, Jack CR Jr, Josephs KA (2011) Clinical correlates of white matter tract degeneration in progressive supranuclear palsy. Arch Neurol 68(6):753–760. https://doi.org/10.1001/archneurol.2011.107 CrossRefPubMedPubMedCentral

39.

de Laat KF, Tuladhar AM, van Norden AG, Norris DG, Zwiers MP, de Leeuw FE (2011) Loss of white matter integrity is associated with gait disorders in cerebral small vessel disease. Brain : J Neurol 134(Pt 1):73–83. https://doi.org/10.1093/brain/awq343 CrossRef

40.

de Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, Jolles J, Breteler MM (2000) Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol 47(2):145–151CrossRefPubMed

Title: Association of homocysteine, folate, and white matter hyperintensities in Parkinson’s patients with different motor phenotypes
Authors: Yuan Shen
Zhi-feng Dong
Ping-Lei Pan
Gang Xu
Jun-Ying Huang
Chun-Feng Liu
Publication date: 01-09-2019
Publisher: Springer International Publishing
Keyword: Parkinson's Disease
Published in: Neurological Sciences / Issue 9/2019
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-019-03906-3

At a glance: The STEP trials

Springer Medicine

Association of homocysteine, folate, and white matter hyperintensities in Parkinson’s patients with different motor phenotypes

Abstract

Objective

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2019

Pseudo carpal tunnel syndrome due to incomplete pure sensory stroke

The neuromodulatory effect of tDCS in patients affected by functional motor symptoms: an exploratory study

Neuropsychological disorders in non-central nervous system cancer: a review of objective cognitive impairment, depression, and related rehabilitation options

Sixth cranial nerve palsy and ipsilateral segmental carotid arteritis after tooth alveolectomy

Cycle ergometer training enhances plasma interleukin-10 in multiple sclerosis

Gender and thrombolysis therapy in acute ischemic stroke patients with incidence of obesity